Alcon Laboratories, Inc.

Kyowa Hakko Kogyo Co., Ltd.

Stella M Robertson

Herman M Kunkle, Jr

John M Yanni

Tadayuki Saito

Hitoshi Tanaka

Shigetoshi Okumura

Laura Smith Lang

Billie M York

Eiji Hayakawa

Masashi Nakakura

Michael E Stern

The use of 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for treating ocular diseases with immune etiology is disclosed.

5-methyl-isoxazole-4-carboxylic acid anilides and

Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating ocular allergies, especially allergic conjunctivitis, giant papillary conjunctivitis, and vernal conjunctivitis.

Ophthalmic compositions comprising emedastine and methods for their use

Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.

Pharmaceutical compositions and methods of treatment of the corneal

Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.

Topical ophthalmic formulations for treating allergic eye diseases

Pharmaceutical compositions and methods of treatment of the cornea

Methods for treating the cornea following UV laser irradiation and resulting photoablation of corneal tissue are disclosed. The methods include administration of compositions of a non-steroidal antiinflammatory to the eye. Compositions for use in treating the cornea are also disclosed.

Compositions and methods for treating the cornea inconjunction with

Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating allergic conjunctivitis and related ailments.

Growing community of inventors

Arlington, TX, United States of America

Stella M Robertson